About Altoida
Altoida is defining a new category in neurological care with a first-of-its-kind, multi-modal platform built to pilot access to clinical-grade cognitive and functional diagnostics at the front line of healthcare. Combining augmented reality (AR), sensor fusion and explainable AI, Altoida's Digital NeuroMarker Platform delivers a 10-minute, self-administered assessment designed for both in-clinic and remote use, capturing hundreds of digital biomarkers across motor, speech, AR and cognitive domains. The platform is intended to detect signs of Mild Cognitive Impairment (MCI) and Alzheimer's disease earlier and more objectively than traditional clinical methods.
Altoida's Digital NeuroMarker Platform is built on more than 20 years of scientific research, shaped by nearly 20,000 participants and tens of thousands of assessments. Featured in Nature Digital Medicine, our platform is already in use by global pharmaceutical leaders to support clinical trial enrichment, optimal screening, treatment monitoring and disease progression research.
By delivering scalable, real-time diagnostics that fit seamlessly into primary care workflows, Altoida aims to expand access to critical cognitive evaluations, empowering providers to identify at-risk individuals earlier and intervene when it matters most. We envision a future where precision brain diagnosis at scale transforms neurological care, accelerates clinical trials, expands access to breakthrough treatments, and supports earlier, more informed decision-making for patients and their loved ones.
With platform extensibility ranging from Parkinson's and traumatic brain injury to depression and beyond, Altoida is building the diagnostic infrastructure for precision brain health at global scale.
Altoida's Digital NeuroMarker Platform has not received FDA clearance and is currently intended for investigational use only.
Altoida's Digital NeuroMarker Platform is built on more than 20 years of scientific research, shaped by nearly 20,000 participants and tens of thousands of assessments. Featured in Nature Digital Medicine, our platform is already in use by global pharmaceutical leaders to support clinical trial enrichment, optimal screening, treatment monitoring and disease progression research.
By delivering scalable, real-time diagnostics that fit seamlessly into primary care workflows, Altoida aims to expand access to critical cognitive evaluations, empowering providers to identify at-risk individuals earlier and intervene when it matters most. We envision a future where precision brain diagnosis at scale transforms neurological care, accelerates clinical trials, expands access to breakthrough treatments, and supports earlier, more informed decision-making for patients and their loved ones.
With platform extensibility ranging from Parkinson's and traumatic brain injury to depression and beyond, Altoida is building the diagnostic infrastructure for precision brain health at global scale.
Altoida's Digital NeuroMarker Platform has not received FDA clearance and is currently intended for investigational use only.